Skip to main content

Lexicon Genetics to Scale Up Functional Genomics Efforts

NEW YORK, April 19 - Lexicon Genetics unveiled a new plan Thursday to determine the in vivo function of 1,000 genes per year for the next five years.

The company plans to find the functions of 5,000 genes, approximately the number of drug targets many scientists believe are encoded in the human genome by 2006, Arthur Sands, Lexicon's CEO, said in a statement.

"Lexicon is amassing the world's largest gene knockout infrastructure, and today we are revealing the magnitude of our capabilities," Sands said.

Lexicon plans to use its knockout gene targeting technology, which generates mice with alterations in specific genes, to determine the function of the 2,500 genes over five years. Lexicon's OmniBank library, which contains clones for about 40 percent of the mammalian genome, will identify the other 2,500 genes, Lexicon said.

To accommodate the company's research efforts, Lexicon, based in The Woodlands, Texas, is adding an additional 300,000 square feet to its physical plant, an addition expected to be complete by the end of the year.  
The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.